HHS reiterates plans to allow Paxlovid access regardless of insurance
Pfizer will charge $1,400 per five-day course of Paxlovid when the drug moves over to commercial sales.
View ArticleWhat is the UK’s Covid-19 drug armoury like amid rising infection levels?
As a new variant spearheads a winter spike in Covid-19 infections in the UK, the range of vaccines and antivirals is very different today to 2020.
View ArticleVGXI’s New Headquarters and Manufacturing Facility, Conroe, Texas
VGXI is building a headquarters and greenfield biomanufacturing facility at the Deison Technology Park in Conroe, Texas.
View ArticleAstraZeneca posts 81% rise in FY 2023 profit after tax
AstraZeneca has reported a significant 81% rise in profit after tax, reaching $5.96bn for FY 2023 from $3.29bn in the previous year.
View ArticleMHRA agrees licence change for Pfizer-BioNTech’s Comirnaty vaccine
The UK MHRA has granted approval for a variation in licence of Pfizer-BioNTech’s Comirnaty XBB.1.5 vaccine targeting Omicron variant.
View ArticleEverest ends Covid-19 mRNA vaccine deal with Providence
China-based Everest will pay $4m upon termination of its partnership agreement with Canada-based Providence.
View ArticleModerna reports net loss of $4.7bn for full year 2023
Moderna has reported a net loss of $4.7bn for the full year 2023 as against a net income of $8.4bn in 2022.
View ArticleMerck reports drop in net income for fiscal 2023
Merck has reported a 15.1% decline in net income attributable to shareholders to €2.82bn in 2023 versus €3.326bn in 2022.
View ArticleQ&A: BARDA wants to back tech that can combat multiple infections, says director
The director of BARDA’s medical countermeasures programs, Robert Johnson, talks about what the agency is planning to invest in the future.
View ArticleJohnson & Johnson reports net earnings of $5.3bn in Q1 2024
Johnson & Johnson has net earnings reaching $5.3bn in Q1 2024 compared to a loss of $491m in the same period of 2023.
View Article
